Adjuvant interferon in the treatment of melanoma – reply by Middleton, M R
Sir
We write in response to the editorial by MR Middleton regarding
the first analysis of the intergroup E1690 trial of high- and low-
dose interferon for high-risk melanoma conducted in the US
between 1990 and 1995. This large trial accrued 642 patients with
resectable deep primaries or node-positive disease to a three-arm
trial of observation, high-dose interferon a-2b (IFN-a-2b) for 1
year or low-dose IFN-a-2b for 2 years. The editorial was submitted
in February, after presentation of this trial’s preliminary analysis to
the ESMO in late 1998. But this study has now been presented in
much greater detail to the American Society of Clinical Oncology,
and is in review for publication. Middleton’s editorial concluded
that the high-dose regimen can not be recommended as the standard
of therapy for high-risk melanoma patients; however, this conclu-
sion is based on very incomplete information, since the data from
E1690 have yet to be fully presented in a formal publication. We
would like to correct a number of errors in the editorial, and urge
the community to carefully consider the data of the formal E1690
trial when they are published this year.
1. In reference to differences in overall survival between the study
population in the E1690 trial and the study population in the
preceding E1684 trial, Dr Middleton writes, ‘This unexpected
difference in the results of the two studies can be explained by
an improvement in the outcome of these patients kept under
observation … [and] may be due to changes in the staging and
surgical techniques: for example, sentinel – node mapping…’.
Response: The E1690 trial results differ most significantly from
E1684 in regard to post-relapse survival of patients in the observa-
tion arm, and this has nothing to do with differences in staging or
surgical technique. In point of fact, very few patients on E1690
were staged using sentinel lymph node biopsy, and none were
assessed as node-positive based on immunochemical or reverse-
transcriptase polymerase chain reaction analyses.
2. Dr Middleton also writes, ‘In the earlier trial, significant differ-
ences in overall survival were only seen amongst patients with
clinically apparent lymphadenopathy prior to resection.’
Response: Significant differences in overall survival in E1684
were seen in the intent-to-treat analysis of the entire population.
These differences, which were statistically significant for the
entire trial, were yet more significant in the histologically node-
positive population, which comprised 89% of the accrual to
E1684. In point of fact, the hazard ratio associated with high-dose
IFN-a-2 therapy on E1684 was greatest (indicating the most
improvement in survival) for patients with clinically negative but
pathologically positive nodes.
We would agree that the lack of efficacy of low-dose IFN-a
observed in the E1690 trial, coupled with the negative results of
the WHO 16 trial of low-dose adjuvant IFN lead to a compelling
conclusion that low-dose IFN-a-2b is less effective than the high-
dose regimen. We would also agree that ‘there seems little doubt
that high-dose interferon has an impact on melanoma, and can
delay the time to relapse in high risk melanoma patients.’
We believe that the consistent improvement in the continuous
relapse-free survival of high-risk melanoma patients receiving
high-dose IFN-a-2b seen in both E1690 and E1684 corroborates
the biologic activity of this regimen. With regard to the survival
benefit observed in E1684, this trial was conducted at a time when
IFN-a was not available for cross-over therapy, and all patients
treated on E1684 had undergone full lymphadenectomy and so had
no opportunity for cross-over. This situation is distinctly at variance
with E1690. In E1690, there was more than a twofold larger
number of patients with clinically negative but unresected
lymphatics, and these patients had the opportunity to cross-over to
IFN-a therapy if they had a regional nodal recurrence. In fact, they
did so in substantial numbers, asymmetrically pursuing IFN
salvage therapy from the observation arm after failure in regional
lymphatics. It is well recognized that regional lymph node relapse
is the most frequent site of relapse in melanoma patients who have
not undergone lymphadenectomy, and this occurrence in more than
40% of the total number of patients treated on E1690, provided an
opportunity for a confounding second exposure to IFN at relapse.
Such was not the case in E1684. A retrospective analysis of salvage
therapy demonstrated significantly greater numbers of patients
from the observation arm than from the high-dose IFN arm were
treated with IFN-a salvage therapy. This provides a plausible
explanation for the differences between the E1684 and E1690 trials
in terms of post-relapse and overall survival outcome.
We would urge the readership to review the data from E1690
when published in J Clin Oncology and to draw their own conclu-
sions. It is our responsibility as oncologists to present the data
regarding high-dose IFN-a-2b to our high-risk melanoma patients
fully and in a balanced fashion. Ultimately, it should be the
patient’s choice to accept or reject treatment.
JM Kirkwood,
Department of Medicine,
University of Pittsburgh Medical Center and
University of Pittsburgh Cancer Institute,
Pittsburgh, PA 15213–2582, USA
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Adjuvant interferon in the treatment of melanoma —
reply
Sir
Although accepted for publication in February 1999 the editorial
in question was amended in proof to take into account Dr
Kirkwood’s presentation to the ASCO congress, as is made clear
DOI: 10.1054/ bjoc.1999.1244, available online at http://www.idealibrary.com on in the text. Dr Kirkwood suggests that there are a number of
‘errors’ in the editorial, but provides no evidence for these,
although there is a difference in our interpretations of the available
data, which is incomplete. In the absence of the definitive report
on E1690 it is reasonable to speculate that stage migration and
changes in surgical technique might explain the difference
between the results and those of E1684. Dr Kirkwood points out
one such change in that twice as many patients had clinically
negative unresected lymphatics in the later study. Only he can
appreciate the role, if any, of sentinel node biopsy until the E1690
results are published.
The editorial acknowledges that overall survival was improved
by high-dose interferon (HDI) in the original study. Amongst the
four sub-groups analysed in the trial report only patients with clin-
ically apparent lymphadenopathy showed a statistically significant
improvement in survival. It is fair to say that the group with clini-
cally negative histologically positive nodes was too small to allow
interpretation of interferon’s efficacy. However, to maintain that
this is the population with the most to gain from HDI on the basis
of a 34 patient sample is tenuous, and not a claim Dr Kirkwood
made in the original report on E1684.
We are agreed that HDI is active in melanoma, and that cross-
over salvage therapy is the most plausible explanation for the
conflicting results obtained. Given its toxicity and the suggestion
that it remains effective at second relapse further work is
required to pinpoint the role of HDI in melanoma. Thus, it is not
possible to commend HDI as the standard adjuvant therapy in
melanoma at high risk of recurrence. Indeed, various cooperative
groups are pursuing trials in this field in which the control arm is
observation only and Schering Plough recently abandoned their
study in resected stage III melanoma in which HDI was the
control arm.
Patients should undoubtedly be informed of the results of both
trials, but only in the USA will they be permitted to accept or
reject treatment. The conflicting results of the E1684 and E1690
studies mean that few purchasers in the UK currently funds HDI
for melanoma at high risk of recurrence. Only patients with the
means to fund treatment themselves will be able to come to their
own decision. The way forward is to design and execute studies
that address the issues thrown up by the imminent publication of
the full E1690 results.
MR Middleton
CRC Department of Medical Oncology,
Christie Hospital NHS Trust, Wilmslow Road,
Withington, Manchester M20 4BX, UK
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Serum tissue polypeptide-specific antigen (TPS):
what is its diagnostic value?
Sir,
We have read with interest an article of Rebhandl et al (1998) on
the diagnostic usefulness of the tissue polypeptide-specific antigen
(TPS) in neuroblastoma and Wilms tumour. We would like to
share our clinical experience with TPS, which is less convincing
than that presented, and have a comment to add on the theoretical
and technical part of the paper.
Traditionally, TPA – summing fragments of (cyto)keratins 8, 18,
19 – and TPS – the soluble fragment of (cyto)keratin 18 – have
been interpreted by some researchers as markers for cell prolifera-
tion (Einarsson and Rylander, 1997; Mishaeli et al, 1998). With the
advent of knowledge on apoptosis it has been found that one of the
central effector molecules, caspase-3, utilizes (cyto)keratin 18 but
not (cyto)keratin 8 as a substrate (Caulin et al, 1997). This recent
observation implies that (cyto)keratin 18 may be specifically
degraded upon receiving an apoptotic stimulus, thus putatively
producing a TPS-like material. We currently explore this concept
on the MCF-7 breast cancer-derived cell line, which is deficient in
caspase-3 (Janicke et al, 1998). Altogether, tumour markers based
on detection of (cyto)keratin fragments, TPA, TPS and CYFRA21-
1 may, at least to some extent, reflect degradative rather than
proliferative cellular events. Apoptosis-inducing antitumour
therapy (cytotoxic drugs, radiotherapy) leads to downstream acti-
vation of caspase-3 in most systems studied (Hannun, 1997). The
question of cleavage products of this reaction with (cyto)keratin
18 as a substrate has not yet been addressed.
In the presence of sepsis and/or renal insufficiency, TPS values
are indeed elevated. However, minor or localized infection and
liver and/or multiorgan failure can also lead to elevation of TPS
with either no apparent underlying malignancy or no change in
stable disease, as we have repeatedly observed in our patients. The
authors state, that ‘these samples were, therefore, excluded’
without giving specific criteria. It should be noted that TPA/TPS
are fairly unspecific biomarkers and for diagnosis are of similar
value as erythocyte sedimentation rate. We assume that diagnoses
in these patients were based on standard techniques. In this sense,
interpreting TPS as a diagnostic marker and assessing its speci-
ficity using ROC after careful a priori elimination of confounders
seems inappropriate, since the TPS value apparently adds nothing
to the diagnostic procedure. On the other hand, data from Table 1
of the paper indicate that TPS could be interpreted as a therapy
response marker (Pronk et al, 1997) as long as variables (intercur-
rent infections, etc.) are under control. It would also be informa-
tive to include comparison with established biomarkers for
neuroblastoma and Wilms’ tumour (catecholamines, NSE). That
‘the potential of TPA in Wilms’ tumour (Ishiwata et al, 1991) have
gone unnoticed in the literature’, as the authors state, may merely
reflect the fact that the TPA value has never contributed new and
clinically relevant information.
At our institute, we performed measurement of TPA for about
8 years (approx. 5500 measurements year–1); 7 months ago we
replaced TPA with TPS Beki (Sweden) due to automation and